Find recruiting clinical trials for MS in the UK — including relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). See your DMT pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Initial disease-modifying therapy after diagnosis
Standard: Interferon beta, Glatiramer acetate, Dimethyl fumarate, or Teriflunomide
After suboptimal response or breakthrough disease activity
Standard: Natalizumab, Fingolimod, Ocrelizumab, or Ofatumumab
Rapidly evolving or aggressive disease course
Standard: Alemtuzumab, Ocrelizumab, or Natalizumab
Secondary or primary progressive disease — fewer approved treatments, trials especially important
Standard: Siponimod (SPMS), Ocrelizumab (PPMS), or clinical trial
About 85% of MS diagnoses. Characterised by episodes of new or worsening symptoms (relapses) followed by periods of recovery (remission). Most DMTs are approved for this form.
Develops in many people with RRMS over time. Steady progression of disability with or without relapses. Fewer treatment options — clinical trials are especially important.
About 10-15% of MS cases. Steady progression from onset without clear relapses. Ocrelizumab is the only approved DMT — trials are critical for new options.
Loading trials from ClinicalTrials.gov...